ABIO (ARCA biopharma) EPS (Basic) : $-6.00 (TTM As of Jun. 2024)

View and export this data going back to 1997. Start your Free Trial

What is ARCA biopharma EPS (Basic)?

ARCA biopharma's basic earnings per share (Basic EPS) for the three months ended in Jun. 2024 was $-2.16. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Jun. 2024 was $-6.00.

ARCA biopharma's EPS (Diluted) for the three months ended in Jun. 2024 was $-2.16. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was $-6.00.

ARCA biopharma's EPS without NRI for the three months ended in Jun. 2024 was $-2.16. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jun. 2024 was -6.00.

During the past 3 years, the average EPS without NRI Growth Rate was 43.70% per year. During the past 5 years, the average EPS without NRI Growth Rate was 47.30% per year. During the past 10 years, the average EPS without NRI Growth Rate was 44.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, ARCA biopharma's highest 3-Year average EPS without NRI Growth Rate was 80.60% per year. The lowest was -86.20% per year. And the median was 37.10% per year.

ARCA biopharma EPS (Basic) Historical Data

The historical data trend for ARCA biopharma's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ARCA biopharma EPS (Basic) Chart

ARCA biopharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Basic)

Get a 7-Day Free Trial

-49.80

-24.84

-16.68

-8.28

-4.44

ARCA biopharma Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
EPS (Basic)	Get a 7-Day Free Trial															-1.20	-1.20	-0.96	-1.68	-2.16

ARCA biopharma EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

ARCA biopharma's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as

Basic EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-5.339	-	0)	/	1.201
	=	-4.45

ARCA biopharma's Basic EPS for the quarter that ended in Jun. 2024 is calculated as

Basic EPS (Q: Jun. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-2.678	-	0)	/	1.209
	=	-2.22

EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.00

ARCA biopharma (NAS:ABIO) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

ARCA biopharma EPS (Basic) Related Terms

Thank you for viewing the detailed overview of ARCA biopharma's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

ARCA biopharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ARCA biopharma Inc (NAS:ABIO) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

10170 Church Ranch Way, Suite 100, Westminster, CO, USA, 80021

Website

https://www.arcabio.com

ARCA biopharma Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. The company's product candidates are rNAPc2 as a potential treatment for COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and potentially other viral diseases and Gencaro for the treatment of atrial fibrillation, or AF, in patients with chronic heart failure, or HF. rNAPc2 targets COVID-19 patients with biomarker evidence of coagulopathy, while Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy.

Executives

James P Flynn	director	41 HARRIS CT, DANVILLE CA 94526
Funicular Funds, Lp	10 percent owner, other: See Footnote 1	2261 MARKET STREET, #4307, SAN FRANCISCO CA 94114
Funicular Fund, Lp	other: See Footnote 1	2261 MARKET STREET, #4307, SAN FRANCISCO CA 94114
Jacob Ma-weaver	other: See Remarks	2261 MARKET STREET, #4307, SAN FRANCISCO CA 94114
Christopher David Ozeroff	officer: S.V.P., General Counsel	8001 ARISTA PLACE, SUITE 200, BROOMFIELD CO 80021
Robert E Conway	director	C/O ARCA BIOPHARMA, INC, 8001 ARISTA PLACE, STE 430, BROOMFIELD CO 80021
C. Jeffrey Dekker	officer: Chief Financial Officer	10170 CHURCH RANCH WAY, WESTMINSTER CO 80021
Thomas A Keuer	officer: Chief Operating Officer	C/O ARCA BIOPHARMA, INC., 10170 CHURCH RANCH WAY, STE 100, WESTMINSTER CO 80021
Brian L. Selby	officer: VP, Finance	11080 CIRCLEPOINT ROAD, SUITE 140, WESTMINSTER CO 80020
Venrock Healthcare Capital Partners Lp	10 percent owner	530 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10036
Scott D Sandell	10 percent owner
David M Mott	10 percent owner	1119 ST. PAUL STREET, BALTIMORE MD 21202
Joshua Makower	10 percent owner	1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Forest Baskett	10 percent owner
Peter J Barris	10 percent owner	1119 ST PAUL STREET, BALTIMORE MD 21202